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Abstract
Background: The elevations of noradrenaline (NA) and serotonin (5-HT) levels in response to
acute serotonin reuptake inhibitor (SSRI) or tricyclic antidepressant (TCA) exposure are not
consistent with the time course for the therapeutic action of these antidepressants. Thus, neuronal
adaptations are needed for the therapeutic effect to arise. Transcription factor Activating Protein
–2 (AP-2) is critical for mammalian neural gene expression. Several genes involved in brainstem
CNS transmitter systems, especially the monoamines, have AP-2 binding sites in their regulatory
regions. We have previously shown that treatment with citalopram and imipramin resulted in a
decrease in AP-2α and AP-2β levels in rat brain. We have also reported an association between a
specific genotype of AP-2β to personality traits, binge-eating disorder and platelet monoamine
oxidase (MAO) activity.
Results: Subchronic administration (10 days) of phenelzine (PLZ) increased the levels of AP-2α,
AP-2β and the DNA binding activity of AP-2 in nuclear extracts prepared from rat whole brain
when compared with sham treated animals.
Conclusion:  These data suggest that AP-2 is not involved in the theraputic effect of
antidepressants. Rather, the effects of antidepressants seen on the levels of AP-2 might be involved
in the expression of side-effects during the lag-period.
Background
It has been suggested that the therapeutic action of antide-
pressant drugs, such as TCAs and SSRIs, are directly related
to their uptake-blocking capability. However, since the
onset in therapeutic action of these drugs usually is
delayed for several weeks, the hypothesis, that the rapid,
acute actions of these drugs in blocking NA and/or 5-HT
reuptake are responsible for the long-term clinical antide-
pressant effect has been questioned, suggesting that their
mechanism of action involves neuronal adaptations [1,2].
Several studies have shown that antidepressant treatment
has effects on transcription factors, which might be
responsible for the neuronal adaptations that are needed
for the therapeutic effect to arise [3–5].
AP-2 is a cell type-specific DNA-binding transcription fac-
tor family of different, yet closely related, proteins with a
molecular weight around 50 kDa. Four different AP-2
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genes, i.e., AP-2α, AP-2β, AP-2γ, and AP-2δ have been
identified [6–9]. AP-2 is one of the critical factors for neu-
ral gene expression in mammals [10]. Several of the genes
involved in brainstem CNS transmitter systems, of funda-
mental importance for behavior, have multiple AP-2
binding sites in their regulatory regions, see [4] and refer-
ences therein. AP-2 binds to GC-rich sequences in the
genome [11]. The cis-acting DNA sequences 5'-(G/
C)CCCA(G/C)(G/C)(G/C)-3' and the palindromic
sequence 5'-GCCNNNGGC-3' are considered as consen-
sus AP-2 binding sites for all AP-2 proteins [12].
AP-2 seems to mediate transcriptional activation in
response to both the phorbol-ester- and diacylglycerol-
activated protein kinase C, and the cAMP-dependent pro-
tein kinase A pathway [7,13].
We have earlier reported that AP-2β genotype is associated
with certain personality traits as estimated by the Karolin-
ska Scales of Personality (KSP) [14], platelet MAO activity
[15] and binge-eating disorder [16]. However, AP-2β gen-
otype was not associated with schizophrenia [17]. Moreo-
ver, brainstem levels of AP-2α and AP-2β were found to be
positively correlated to forebrain monoamine levels in
adult rats, e.g. 5-HT turnover and NA-levels in frontal cor-
tex [18]. We have previously shown that subchronic treat-
ment with citalopram (CIT) and imipramin (IMN)
resulted in a decrease in AP-2α and AP-2β levels and
DNA-binding activity of AP-2 in rat whole brain [4]. In the
present study, we report that subchronic treatment with
the non-selective MAO-inhibitor (MAO-I) PLZ resulted in
an increase in both AP-2α and AP-2β levels and DNA-
binding activity of AP-2.
Results
Subchronic administration (10 days) of PLZ significantly
increased the DNA binding activity of AP-2 in nuclear
extracts prepared from rat whole brain when compared
with sham treated animals (Fig. 1), i.e. 1.57 ± 0.095
(Range: 1.45–1.60), compared with 0.688 ± 0.204
(Range: 0.38–0.91) (mean relative optical density ± SD, p
< 0.0001). Representative EMSA gels for PLZ and Sham
treated animals are shown in figure 2 (Fig. 2). One single
band was seen on EMSA gels after an overnight exposure,
which supposedly represents AP-2 binding to the labelled
probe. By including different concentrations of cold AP-2
probe in the binding reaction, AP-2 binding to the
labelled probe was reduced with increased concentration
of cold AP-2 probe. A 50 fold excess of a non-labelled AP-
2 probe almost completely blocked binding to labelled
probe. In contrast, when a 50 fold excess of a non-labelled
mutated AP-2 probe or a non-labelled AP-1 probe was
included in the binding reaction, AP-2 binding was not
affected (Fig. 3)
When analysing the level of AP-2α, there was a tendency
that AP-2α was increased in the PLZ treated rats, i.e. 7.43
± 2.88 (Range: 4.94–10.48) compared with 4.11 ± 2.03
(Range: 1.61–6.26) (mean relative OD ± SD, p = 0.068)
(Fig. 4a). The level of AP-2β protein was increased in the
PLZ treated rats in comparison to sham treated animals,
i.e. 5.86 ± 0.63 (Range: 5.13–6.80) compared with 4.30 ±
0.62 (Range: 3.51–4.92) (mean relative OD ± SD, p =
0.0043) (Fig. 4b).
Discussion
Several research groups are currently discussing the possi-
bility that serotonergic gene transcriptional control
regions, or transcription factors themselves, could be
future targets for antidepressant drugs [16,19–22].
We have previously shown an effect of treatment with CIT
and IMN on AP-2 in rat brain. Both drugs decreased the
levels of AP-2α, AP-2β and DNA-binding activity of AP-2
after 10 days of treatment [4]. The present data regarding
PLZ, an unselective irreversible inhibitor of MAO-A and
MAO-B, goes in the opposite direction. The reason for this
could be explained in several ways. Blier and de Montigny
(1998) suggested that long-term administration of MAO-
Is had different effects on both terminal autoreceptor- and
postsynaptic responsiveness than SSRIs [23]. These differ-
ent effects on receptor responsiveness would explain dif-
ferencies in downstream effects on AP-2 after treatment
with MAO-I and SSRIs.
Treatment with PLZ (10 days) increases the DNA-binding  activity of AP-2 in rat brain Figure 1
Treatment with PLZ (10 days) increases the DNA-binding 
activity of AP-2 in rat brain. Relative DNA binding activity of 
AP-2 was determined by EMSA analyses on nuclear extracts 
prepared from rat brain. PLZ treated animals were com-
pared with a sham treated control group. The results were 
considered statistically significant when p < 0.05.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/10
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Representative EMSA autoradiograms showing A) PLZ and B) sham treated animals Figure 2
Representative EMSA autoradiograms showing A) PLZ and B) sham treated animals. Each group consisted of five rats and each 
rat was analysed twice for accuracy.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/10
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A representative EMSA autoradiogram showing the specificity of binding to the labelled AP-2 probe is shown Figure 3
A representative EMSA autoradiogram showing the specificity of binding to the labelled AP-2 probe is shown. Arrows indicate 
the main band considered as AP-2 binding to the labelled probe, free probe is also indicated.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/10
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It has been shown that treatment with PLZ displays an
increase in the levels of brain monoamines after one
week, but that levels of NA, 5-HT and 5-hydroxyin-
doleacetic acid (5-HIAA) return to baseline levels after
two weeks, even though MAO activity remained signifi-
cantly inhibited at these times [24]. We have previously
shown that CIT treated rats displayed significantly lower
levels of AP-2α and AP-2β and DNA-binding activity of
AP-2 after 7 days of treatment, and that those levels were
normalised after 21 days [5]. This is in line with the fact
that we, in another study, have found positive correlations
between brainstem levels of AP-2α and AP-2β and 5-HT
turnover and levels of NA in the forebrain of rats [18]. The
lag period observed before therapeutic onset with antide-
pressants is associated with several side-effects, and even
an increased risk for suicide. One may speculate that the
down-regulation of AP-2 seen after treatment with CIT
and IMN, as well as the up-regulation seen after PLZ treat-
ment, are not involved in the theraputic effect of these
antidepressants. Rather, the effects of antidepressants seen
on the levels of AP-2 might be involved in the expression
of side-effects during the lag-period.
We have previously reported an association between AP-
2β genotype and platelet monoamine oxidase B activity
[15]. Thus, it seems as if transcription factor AP-2 is
involved in the regulation of MAO-B gene expression.
One way to explain the increase in AP-2 levels and DNA-
binding activity after PLZ treatment would be that when
blocking MAO-B with PLZ there is an up-regulation of AP-
2 in order to compensate for the decreasing amount of
MAO-B enzyme.
Conclusions
An increased knowledge of the molecular mechanisms
involved in the initial lag-period before the therapeutic
effect of antidepressant treatment, might make it possible
to generate compounds with a faster therapuetic onset
and less side-effects. The use of a new class of compounds
directly affecting transcription factor mechanisms is cur-
rently discussed [16,19–22].
Methods
Adult, male Sprague-Dawley rats (10 weeks of age, B–K
Universal AB, Sollentuna, Sweden) were housed in groups
of five with food and water ad libitum. Animals were
administered PLZ (10 mg/kg, KEBO, Stockholm, Sweden)
subcutaneously with daily injections for 10 days. PLZ was
dissolved in saline (NaCl, 9 mg/ml, Pharmacia – Upjohn,
Uppsala, Sweden). Sham treated animals recieved saline
injections of the same volume as that given for drug treat-
ments. The animals were sacrificed 24 hours after the final
injection. After sacrifice the cerebrum was dissected and
the right hemispheres were prepared for electrophoretic
mobility shift assay (EMSA) and Enzyme-Linked Immu-
nosorbent Assay (ELISA) analyses. The study was
approved by the local ethics committee.
Nuclear proteins were extracted essentially according to
the protocol by Dignam and co-workers [25]. For the
EMSA analyses the AP-2 consensus dsDNA oligos (5'-
GATCGAACTGACCGCCCGCGGCCCGT-3') were 5'-end
labelled with T4 polynucleotide kinase according to the
manufacturer (United States Biochemical, Cleveland,
Relative levels of AP-2α and AP-2β were determined by  ELISA analyses after 10 days of PLZ treatment Figure 4
Relative levels of AP-2α and AP-2β were determined by 
ELISA analyses after 10 days of PLZ treatment. A) There is a 
tendency that PLZ treatment increases levels of AP-2α in rat 
brain. B) Treatment with PLZ increases levels of AP-2β in rat 
brain. The results were considered statistically significant 
when p < 0.05.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/10
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Ohio). Typically, the labelled probes had a specific activ-
ity of ~2 × 105 cpm/pmol DNA.
The EMSA binding reaction was carried out as previously
described [5]. The DNA-binding activity of AP-2 was ana-
lyzed in relation to each of the different treatment groups.
Each treatment group consisted of five rats and each rat
was analysed twice for accuracy. The dsDNA probe used in
the EMSA analyses in order to analyse the DNA binding
activity of AP-2 has been used in many other studies of
AP-2 and it has been confirmed that AP-2 binds to the
probe by interacting with the AP-2 consensus site [4].
The ELISA was performed as previously described [5]. The
plates were analysed in an ELISA reader (Molecular
Devices, Thermo Max) at optical density (OD) 405/490.
The OD of the AP-2 isoforms for each rat was correlated to
a value in a standard curve, where known concentrations
of antibody are plotted against optical denisty. The value
from the standard curve was then divided with the con-
centration of the total protein in the nuclear extracts. The
quota was used as a relative amount of AP-2α and AP-2β.
Each treatment group consisted of five rats and each rat
was analysed twice for accuracy.
The statistical comparisons between PLZ treated rats and
controls were done by the use of Student's t-test. All calcu-
lations were performed using StatView 5.0 software (SAS
Institute Inc., Cary, NC, USA). Results have been consid-
ered statistically significant when p < 0.05.
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